sorafenib has been researched along with Melanoma in 123 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 40 (32.52) | 29.6817 |
2010's | 77 (62.60) | 24.3611 |
2020's | 6 (4.88) | 2.80 |
Authors | Studies |
---|---|
Dalton, JT; Li, W; Lu, Y; Miller, DD; Wang, Z | 1 |
Chen, J; Dalton, JT; Li, W; Lu, Y; Miller, DD; Wang, Z | 1 |
Cho, SJ; Choi, JH; Hah, JM; Kim, DJ; Kim, H; Lee, SH; Nam, BS; Oh, CH; Sim, TB; Yoo, KH | 1 |
Davies, L; Dijkstra, HP; Friedlos, F; Gill, A; Kirk, R; Manne, HA; Marais, R; Ménard, D; Niculescu-Duvaz, D; Niculescu-Duvaz, I; Nourry, A; Roman, E; Springer, CJ; Suijkerbuijk, BM; Taylor, RD; Whittaker, S; Zambon, A | 1 |
Baek, D; Cho, JH; Choi, WK; El-Gamal, MI; Hah, JM; Jung, MH; Kim, H; Lee, SH; Oh, CH; Park, JH; Sim, TB; Yoo, KH | 1 |
Cho, JH; Choi, JH; El-Gamal, MI; Hah, JM; Hong, JH; Jung, MH; Kim, H; Kim, HJ; Lee, SH; Oh, CH; Sim, TB; Yoo, KH | 1 |
Chung, JY; Hah, JM; Kim, H; Lee, J; Oh, CH; Sim, T; Yoo, KH; Yu, H | 1 |
Hah, JM; Jung, Y; Kim, H; Lee, J; Oh, CH; Sim, T; Yoo, KH; Yu, H | 1 |
Cho, SJ; Hah, JM; Kim, DJ; Kim, H; Lee, J; Lee, SH; Nam, BS; Oh, CH; Sim, TB; Tae, J; Yoo, KH | 1 |
Hah, JM; Kim, H; Kim, M; Kim, MH; Sim, T; Yoo, KH; Yu, H | 1 |
El-Gamal, MI; Jung, MH; Lee, WS; Oh, CH; Sim, T; Yoo, KH | 1 |
Baek, D; Choi, HS; Choi, WK; El-Gamal, MI; Oh, CH | 1 |
Hah, JM; Kim, H; Kim, M; Lee, J; Yu, H | 1 |
El-Gamal, MI; Lee, YS; Oh, CH; Park, JH | 1 |
Li, CY; Li, QS; Lu, X; Zhang, H; Zhu, HL | 1 |
Cho, HJ; El-Gamal, MI; Hah, JM; Kim, H; Kim, HJ; Lee, SH; Oh, CH; Sim, T; Yoo, KH | 1 |
Abdel-Maksoud, MS; El-Gamal, MI; Jung, MH; Oh, CH; Sim, T; Yoo, KH | 1 |
Dong, JJ; Li, QS; Lv, XH; Yang, Y; Zhang, YB; Zhou, WP; Zhu, HL | 1 |
Choi, HS; El-Gamal, MI; Hong, JH; Kim, G; Koh, EJ; Lee, SG; Lee, SH; Oh, CH; Sim, T; Yoo, KH | 1 |
Chen, K; Li, B; Shen, J; Wang, G; Wang, H; Xu, Z; Yang, M; Zeng, B; Zhu, W | 1 |
Chen, Y; Lu, T; Mao, T; Tang, W; Wang, L; Zhang, L; Zhang, Q; Zhang, Z; Zhi, Y; Zhou, X; Zhu, G | 1 |
Li, Z; Liu, P; Niu, F; Qian, L; Ren, Y; Wang, C; Wang, J; Xiong, Y; Yan, Y; Ye, Q; Yu, Y | 1 |
Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
Antunes, F; Bincoletto, C; Buri, MV; Chammas, R; Corazzari, M; Fimia, GM; Gagliardi, M; Pereira, GJS; Piacentini, M; Saito, RF; Smaili, SS | 1 |
Jung, KE; Kim, CD; Kim, KI; Shin, YB; Yoon, TJ | 1 |
Anbar, HS; El-Gamal, MI; Jeon, HR; Kwon, D; Lee, BS; Oh, CH; Tarazi, H | 1 |
Ebrahim, S; Hashemi, S; Moosavi, MA; Motamedi, M; Rahmati, M | 1 |
Heinzerling, L; Janka, R; Kaempgen, E; Knieling, F; Neurath, MF; Scheulen, ME; Schuler, G; Strobel, D; Sturm, J; Wildner, D | 1 |
Lim, SY; Menzies, AM; Rizos, H | 1 |
Moorthy, A; Srivastava, A | 1 |
In, GK; Ricker, C; Snow, A | 1 |
Pavlick, AC | 1 |
Allegra, M; Bahadoran, P; Ballotti, R; Giacchero, D; Hofman, P; Lacour, JP; Le Duff, F; Long-Mira, E; Passeron, T | 1 |
Degen, A; Egberts, F; Garbe, C; Gutzmer, R; Hauschild, A; Kilian, K; Poppe, LM; Trefzer, U; Ugurel, S; Weichenthal, M | 1 |
Allegra, M; Bahadoran, P; Ballotti, R; Bastian, BC; Bollag, G; Botton, T; Burton, EA; Garrido, MC; LeBoit, PE; McCalmont, TH; Nelson, T; Rocchi, S; Sparatta, A; Vemula, SS; Yeh, I | 1 |
Aupérin, A; Ayyoub, M; Caignard, A; Caillat-Zucman, S; Chaba, K; Chaput, N; Dessen, P; Eggermont, A; Flament, C; Jacquelot, N; Jacques, Y; Mateus, C; Messaoudene, M; Mortier, E; Poirier-Colame, V; Porta, C; Robert, C; Romero, AI; Rusakiewicz, S; Valmori, D; Vielh, P; Zitvogel, L | 1 |
Bhinder, A; Carson, WE; Clinton, SK; Geyer, S; Kendra, K; Lam, E; Lesinski, GB; Mace, TA; Monk, P; Mortazavi, A; Olencki, T; Tahiri, S | 1 |
Holderfield, M; Nagel, TE; Stuart, DD | 1 |
D'Andrea, K; Flaherty, KT; Kirkwood, JM; Kluger, HM; Lee, SJ; Letrero, R; Nathanson, KL; Rimm, DL; Schuchter, LM; Wilson, MA; Zhao, F | 1 |
Aigner, B; Artl, M; Niederkorn, A; Richtig, E; Schwantzer, G; Wackernagel, W | 1 |
Beeram, M; Benjamin, D; Ketchum, N; Mahalingam, D; Malik, L; Michalek, J; Mita, A; Rodon, J; Sankhala, K; Sarantopoulos, J; Tolcher, A; Wright, J | 1 |
Gadot, N; Lassau, N; Leguerney, I; Pénault-Llorca, F; Robin, N; Scoazec, JY; Victorin, S | 1 |
Anseth, KS; Jones, CE; Leight, JL; Lin, AJ; Tokuda, EY | 1 |
Aldridge, J; Atkins, MB; Conley, C; Flaherty, KT; Giobbie-Hurder, A; Hodi, FS; Ibrahim, N; Lawrence, DP; McDermott, DF; Mier, JW; Sullivan, RJ | 1 |
Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT | 1 |
Afaq, F; Agarwal, J; Athar, M; Baxter, RD; Elmets, CA; Hunt, KM; Pal, HC | 1 |
D'Andrea, K; Flaherty, KT; Khare, S; Kirkwood, JM; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Roszik, J; Schuchter, LM; Wilson, MA; Woodman, SE; Wubbenhorst, B; Zhao, F | 1 |
Afaq, F; Athar, M; Diamond, AC; Elmets, CA; Kappes, JC; Katiyar, SK; Pal, HC; Strickland, LR | 1 |
Henderson, M; Heriot, AG; Knowles, J; Lynch, AC; Warrier, SK | 1 |
Fiskus, W; Mitsiades, N | 1 |
Okano, S | 1 |
Chen, H; Fisher, DE; Li, Y; Sun, J; Westover, KD; Xia, Y; Zhang, J | 1 |
Delcambre, C; Dutriaux, C; Heutte, N; Joly, F; Lesimple, T; Mouriaux, F; Neidhart-Berard, EM; Parienti, JJ; Penel, N; Peyro Saint Paul, L; Pham, AD; Piperno-Neumann, S; Servois, V; Thyss, A | 1 |
Kester, M; Robertson, GP; Smith, CD; Tran, MA | 1 |
Egberts, F; Hauschild, A; Kahler, KC; Livingstone, E | 1 |
Amaravadi, R; Fecher, LA; Schuchter, LM | 1 |
Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; McClure, R | 1 |
Bar-Eli, M; Melnikova, VO | 1 |
Jorda, E; Lopez, V; Marti, N; Monteagudo, C; Pinazo, I | 1 |
Elder, DE; Flaherty, KT; Herlyn, M; Letrero, R; Nathanson, KL; Nguyen, TK; Smalley, KS; Van Belle, P; Villanueva, J; Wang, Y; Xiao, M | 1 |
Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N | 1 |
Hwu, P; Kim, K; Lazar, AJ; Quintás-Cardama, A; Ross, M; Woodman, SE | 1 |
Poust, J | 1 |
Camp, RL; Flaherty, KT; Jilaveanu, L; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Zito, C | 1 |
Lee, F; Richmond, A; Smykla, R; Thu, YM; Yang, J; Zaja-Milatovic, S | 1 |
Dhomen, N; Marais, R | 1 |
Frieling, T; Heise, J; Wassilew, SW | 1 |
Flaherty, KT; Smalley, KS | 1 |
Subbiah, V; Wolff, JE | 1 |
Aziz, SA; Camp, RL; Conrad, PJ; Jilaveanu, LB; Kluger, HM; Rimm, DL; Schmitz, JC; Sznol, M; Zito, CR | 1 |
Gil, R; Grueso, J; Hernandez-Losa, J; López-Fauqued, M; Moliné, T; Pujol, A; Recio, JA | 1 |
DeNicola, GM; Karreth, FA; Tuveson, DA; Winter, SP | 1 |
Bertsch, A; Henneges, C; Jung, S; Kohlbacher, O; Nahnsen, S; Nordheim, A; Pfeifer, N; Zerck, A | 1 |
Hurlstone, A; Wellbrock, C | 1 |
Dobrovic, A; Hamilton, AL; Handolias, D; Kerr, L; McArthur, GA; Moodie, K; Salemi, R; Tan, A | 1 |
Burger, AM; Egorin, MJ; Heilbrun, LK; Horiba, MN; Ivy, P; Li, J; Lorusso, PM; Pacey, S; Sausville, EA; Vaishampayan, UN | 1 |
Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA | 1 |
Degen, A; Gutzmer, R; Hauschild, A; Kapp, A; Satzger, I; Voelker, B | 1 |
Beck, D; Berger, A; Flaherty, K; Garbe, C; Gogel, J; Kulms, D; Lasithiotakis, K; Maczey, E; Mauthe, M; Meier, F; Niessner, H; Proikas-Cezanne, T; Schadendorf, D; Schaller, M; Schittek, B; Sinnberg, T; Toulany, M; Venturelli, S | 1 |
Rosen, N; Solit, D | 1 |
Nelson, KC; Puri, PK; Raymond, AK; Selim, MA; Tyler, DS | 1 |
Buckley, M; Christos, PJ; Goldberg, L; Hamilton, A; Liebes, L; Min, C; Osman, I; Ott, PA; Pavlick, AC; Polsky, D; Safarzadeh-Amiri, S; Wright, JJ; Yee, H; Yoon, J | 1 |
Becker, JC; Berking, C; Degen, A; Egberts, F; Frey, L; Garbe, C; Gutzmer, R; Hassel, JC; Hauschild, A; Kaehler, KC; Livingstone, E; Mauch, C; Mohr, P; Rass, K; Schadendorf, D; Schenck, F; Trefzer, U; Ugurel, S; Weichenthal, M; Wilhelm, T | 1 |
Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D | 1 |
Fliegel, L; Karki, P; Li, X; Schrama, D | 1 |
Flaherty, KT; Frye, RF; Lathia, C; O'Dwyer, PJ; Redlinger, M; Rosen, M; Schuchter, L | 1 |
Bell, JC; Breitbach, CJ; Falls, T; Heo, J; Hickman, T; Hwang, TH; Kim, CW; Kim, MK; Kirn, DH; Lee, YK; Moon, A; Oh, SY; Parato, K; Patt, R; Rhee, BG; Rintoul, J; Woo, HY | 1 |
Bertolotto, C; Bourcier, C; Grépin, R; Griseri, P; Mazure, N; Pagès, G | 1 |
Boulinguez, S | 1 |
Affolter, A; Ahmad, T; Chao, D; Chevreau, C; Corrie, P; Eisen, T; Gibbens, I; Gore, ME; Harries, M; James, MG; Jouary, T; Lorigan, P; Marais, R; Montegriffo, E; Nathan, PD; Negrier, S; Ottensmeier, C; Prendergast, S; Robert, C; Strauss, UP | 1 |
Bedeir, A; Berger, W; Ghassemi, S; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Heinzle, C; Held, G; Holzmann, K; Marian, B; Metzner, T; Micksche, M; Peter-Vörösmarty, B; Pirker, C; Spiegl-Kreinecker, S | 1 |
Bollag, G | 1 |
Chan, JL; Chen, S; Goydos, JS; Lee, HJ; Namkoong, J; Rosenberg, S; Shin, SS; Wall, BA; Wangari-Talbot, J | 1 |
Liu, Q; Mier, JW; Panka, DJ | 1 |
Cho, HG; Choi, HS; El-Gamal, MI; Hong, JH; Oh, CH; Yoo, KH | 1 |
Doudican, NA; Orlow, SJ; Quay, E; Zhang, S | 1 |
Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Deville, A; Giacchero, D; Lacour, JP; Ortonne, JP; Passeron, T; Ségalen, C; Thyss, A | 1 |
Bassett, RL; Bedikian, AY; Culotta, KS; Dancey, JE; Davies, MA; Deng, W; Fox, PS; Gupta, S; Huang, S; Hwu, P; Hwu, WJ; Kim, KB; Lazar, AJ; Liu, W; Madden, TL; Ng, CS; Papadopoulos, NE; Prieto, VG; Wright, JJ; Xu, Q | 1 |
Akerley, WL; Flaherty, LE; Kirkwood, JM; Lao, CD; Margolin, KA; Moon, J; Othus, M; Sondak, VK; Sosman, JA | 1 |
Dummer, R; Karpova, MB; Levesque, MP; Mangana, J | 1 |
Augustine, C; Beasley, GM; Brady, MS; Coleman, AP; Davies, MA; Peterson, BL; Raymond, A; Sanders, G; Selim, MA; Tyler, DS | 1 |
Avril, MF; Billemont, B; Blanchet, B; Coriat, R; Franck, N; Goldwasser, F; Lebbe, C; Mir, O; Pécuchet, N; Tod, M; Viguier, M | 1 |
Bornfeld, N; Freistuehler, M; Hilger, RA; Scheulen, M; Steuhl, KP; Westekemper, H | 1 |
Axelrod, M; Capaldo, BJ; Gioeli, D; Jensen, K; Mackey, A; Roller, DG; Weber, MJ | 1 |
Aparicio, AM; Bhatia, S; Lao, CD; Margolin, KA; Moon, J; Othus, M; Ribas, A; Sondak, VK; Weber, JS | 1 |
Atkins, MB; Flaherty, KT; Flaherty, L; Kefford, R; Kirkwood, JM; Lee, SJ; Leming, P; Schuchter, LM; Zhao, F | 1 |
Chiloeches, A; Friedlos, F; Hayward, R; Hedley, D; Karasarides, M; Marais, R; Marshall, CJ; Martin, J; Niculescu-Duvaz, D; Ogilvie, L; Scanlon, I; Springer, CJ | 1 |
Robertson, GP; Sharma, A; Smith, CD; Trivedi, NR; Tuveson, DA; Zimmerman, MA | 1 |
Atkins, MB; Mier, JW; Panka, DJ; Wang, W | 1 |
Rini, BI | 1 |
Ahmad, T; Eisen, T; Flaherty, KT; Gibbens, I; Gore, M; Hackett, S; James, M; Kaye, S; Marais, R; Nathanson, KL; O'Dwyer, PJ; Poulin-Costello, M; Ratain, MJ; Schuchter, LM; Schwartz, B; Simantov, R; Xia, C | 1 |
Carter, C; Gollob, JA; Kelley, SL; Wilhelm, S | 1 |
Carter, C; Feldman, MD; Lassoued, W; Lee, WM; Makonnen, S; Murphy, DA | 1 |
Angevin, E; Armand, JP; Brendel, E; Chami, L; Escudier, B; Lamuraglia, M; Landreau, V; Lassau, N; Robert, C; Schwartz, B; Soria, JC; Zafarana, E | 1 |
Hauschild, A | 1 |
Busch, S; Garbe, C; Herlyn, M; Kulms, D; Lasithiotakis, K; Maczey, E; Meier, F; Schittek, B | 1 |
Acs, G; Brafford, P; Chen, L; Edwards, R; Herlyn, M; Kazianis, S; Kumar, SM; Xu, X; Yu, H | 1 |
Flaherty, KT | 1 |
Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI | 1 |
Atkins, MB; Cho, DC; Mier, JW; Panka, DJ | 1 |
Flaherty, KT; Garbe, C; Kulms, D; Lasithiotakis, KG; Maczey, E; Meier, FE; Schittek, B; Sinnberg, TW | 1 |
Hersey, P; Hong, A; Moncrieff, M; Shannon, K; Thompson, J | 1 |
Agarwala, S; Beeram, M; Cranmer, L; Frenette, G; Gonzalez, R; Hersh, E; Hodi, FS; Jakub, JW; Kirkwood, J; Lewis, K; Linette, GP; McDermott, DF; Patel, K; Puzanov, I; Richards, J; Sosman, JA; Tarantolo, S; White, JM; Xia, C | 1 |
14 review(s) available for sorafenib and Melanoma
Article | Year |
---|---|
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
New insights on the role of autophagy in the pathogenesis and treatment of melanoma.
Topics: Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Carcinogenesis; Gene Expression; Humans; Melanoma; Skin Neoplasms; Sorafenib | 2020 |
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2017 |
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Enzyme Activation; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Multimerization; Protein Processing, Post-Translational; raf Kinases; Sorafenib; Sulfonamides; Vemurafenib | 2014 |
[New molecular target therapy for thyroid neoplasms and malignant melanomas].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Quinolines; Skin Neoplasms; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib | 2015 |
Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Science; Skin Neoplasms; Sorafenib; Treatment Outcome | 2008 |
BRAF signaling and targeted therapies in melanoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Drugs, Investigational; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Humans; Melanoma; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2009 |
BRAF as therapeutic target in melanoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib | 2010 |
Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Female; Humans; Male; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib | 2010 |
Sorafenib in melanoma.
Topics: Animals; Benzenesulfonates; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2012 |
Sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2006 |
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Extracellular Signal-Regulated MAP Kinases; Melanoma; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Isoforms; Protein Kinase Inhibitors; Pyridines; raf Kinases; Signal Transduction; Sorafenib | 2006 |
[Clinical studies with sorafenib (Nexavar) in metastatic melanoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib; Treatment Outcome | 2007 |
Sorafenib: delivering a targeted drug to the right targets.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib | 2007 |
23 trial(s) available for sorafenib and Melanoma
Article | Year |
---|---|
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Causality; Comorbidity; Drug Eruptions; Female; Germany; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Prevalence; Recombinant Proteins; Risk Factors; Skin Neoplasms; Sorafenib; Treatment Outcome | 2013 |
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.
Topics: Adult; Aged; CD4 Antigens; Cell Growth Processes; Female; Humans; Interleukin-15; Interleukin-15 Receptor alpha Subunit; Male; Melanoma; Middle Aged; Niacinamide; NK Cell Lectin-Like Receptor Subfamily K; Phenylurea Compounds; Sorafenib; Th1 Cells; Young Adult | 2014 |
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Interleukin-2; Kidney Neoplasms; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; STAT5 Transcription Factor; T-Lymphocytes, Regulatory | 2014 |
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Double-Blind Method; Female; Follow-Up Studies; Genotype; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Survival Rate | 2014 |
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Disease Progression; Drug Monitoring; Early Termination of Clinical Trials; Feasibility Studies; Female; Hand-Foot Syndrome; Humans; Hypertension; Kinetics; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Sorafenib; Vascular Endothelial Growth Factors | 2014 |
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; Double-Blind Method; Genes, ras; Humans; Melanoma; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Sorafenib; Treatment Outcome | 2016 |
Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Male; Melanoma; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Uveal Neoplasms | 2016 |
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Cell Line, Tumor; Disease-Free Survival; Drug Delivery Systems; Humans; Melanoma; Mitogen-Activated Protein Kinase 3; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib; Treatment Outcome | 2009 |
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzoquinones; Clinical Trials, Phase II as Topic; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lactams, Macrocyclic; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2010 |
A phase II trial of sorafenib in metastatic melanoma with tissue correlates.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Cyclin D1; DNA Mutational Analysis; Female; Humans; Ki-67 Antigen; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sequence Analysis, DNA; Signal Transduction; Sorafenib | 2010 |
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Benzenesulfonates; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Prospective Studies; Pyridines; Recombinant Proteins; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Topics: Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Isoenzymes; Melanoma; Midazolam; Niacinamide; Omeprazole; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib | 2011 |
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome | 2012 |
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Melphalan; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Array Analysis; Skin Neoplasms; Sorafenib; Tissue Distribution | 2012 |
Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib | 2012 |
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib; Treatment Outcome; Uvea; Uveal Neoplasms | 2012 |
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; DNA Primers; Female; Genes, ras; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Proto-Oncogene Proteins B-raf; Pyridines; Safety; Sorafenib | 2006 |
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Immune System; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Treatment Outcome | 2007 |
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome; United States | 2008 |
86 other study(ies) available for sorafenib and Melanoma
Article | Year |
---|---|
Synthesis and antiproliferative activity of thiazolidine analogs for melanoma.
Topics: Cell Line, Tumor; Cell Proliferation; Humans; Melanoma; Thiazolidines | 2007 |
Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Imidazolines; Melanoma; Structure-Activity Relationship; Thiazolidines | 2008 |
Aminoquinoline derivatives with antiproliferative activity against melanoma cell line.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Melanoma | 2009 |
Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.
Topics: Allosteric Site; Antineoplastic Agents; Inhibitory Concentration 50; Melanoma; Mutation, Missense; Phenols; Proto-Oncogene Proteins B-raf; Pyridines; Structure-Activity Relationship | 2009 |
Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Melanoma; Molecular Structure; Pyrimidines; Pyrroles; Stereoisomerism; Structure-Activity Relationship | 2009 |
Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Structure-Activity Relationship | 2010 |
Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Drug Discovery; Humans; Imidazoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-raf; Pyridines; Pyrimidines; Sorafenib; Structure-Activity Relationship | 2010 |
1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Inhibitory Concentration 50; Melanoma; Protein Kinase Inhibitors; raf Kinases; Structure-Activity Relationship | 2010 |
Synthesis of aminoquinazoline derivatives and their antiproliferative activities against melanoma cell line.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromones; Humans; Melanoma; Quinazolines; Structure-Activity Relationship | 2010 |
Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.
Topics: Amides; Antineoplastic Agents; Benzenesulfonates; Binding Sites; Cell Line, Tumor; Computer Simulation; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyridines; raf Kinases; Sorafenib; Structure-Activity Relationship | 2011 |
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Skin Neoplasms; Sorafenib; Structure-Activity Relationship | 2011 |
New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; MAP Kinase Signaling System; Melanoma; Models, Molecular; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazoles; Structure-Activity Relationship | 2011 |
Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
Topics: Amides; Azepines; Cell Growth Processes; Cell Line, Tumor; Humans; Melanoma; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Pyrazoles; Structure-Activity Relationship; U937 Cells | 2011 |
New imidazo[2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation, and in silico studies.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Structure-Activity Relationship; Thiazoles | 2011 |
Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; Chalcone; Chalcones; Drug Design; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Melanoma; Molecular Structure; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Structure-Activity Relationship; Sulfones | 2012 |
New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: design, synthesis, and antiproliferative activity against melanoma cell line.
Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Melanoma; Urea | 2012 |
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Humans; Melanoma; Pyridines; Pyrroles; Structure-Activity Relationship | 2012 |
Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents.
Topics: Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Melanoma; Phosphorylation; Protein Binding; Proto-Oncogene Proteins B-raf; Pyrazoles; Quantitative Structure-Activity Relationship; Salicylamides | 2012 |
New diarylamides and diarylureas possessing 8-amino(acetamido)quinoline scaffold: synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition, and in silico studies.
Topics: Acetamides; Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship; Urea | 2013 |
Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
Topics: Antineoplastic Agents; Benzazepines; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; HCT116 Cells; Hep G2 Cells; Humans; Indoles; K562 Cells; Melanoma; Molecular Structure; Niacinamide; Phenylurea Compounds; Quinolones; Sorafenib; Structure-Activity Relationship; Sulfonamides; Vemurafenib | 2013 |
Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Humans; Melanoma; Protein Kinase Inhibitors; Pyrimidines; raf Kinases; Rats | 2017 |
Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma.
Topics: Arginase; Cell Death; Ferroptosis; Humans; Melanoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sorafenib | 2022 |
Effective Synergy of Sorafenib and Nutrient Shortage in Inducing Melanoma Cell Death through Energy Stress.
Topics: Antineoplastic Agents; Autophagy; Cell Death; Humans; Melanoma; Nutrients; Sorafenib; Tumor Microenvironment | 2020 |
Sorafenib induces pigmentation via the regulation of β-catenin signalling pathway in melanoma cells.
Topics: Antineoplastic Agents; beta Catenin; Cell Line, Tumor; Humans; Melanoma; Pigmentation; Signal Transduction; Skin Neoplasms; Sorafenib | 2022 |
Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies.
Topics: Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Molecular Dynamics Simulation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quantitative Structure-Activity Relationship; Sorafenib; Sulfonamides; Thiazoles; Vemurafenib | 2020 |
Assessment of sorafenib induced changes in tumor perfusion of uveal melanoma metastases with dynamic contrast-enhanced ultrasound (DCE-US).
Topics: Contrast Media; Humans; Melanoma; Perfusion; Prospective Studies; Sorafenib; Ultrasonography; Uveal Neoplasms | 2022 |
Sorafenib induces synergistic effect on inhibition of vemurafenib resistant melanoma growth.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Melanoma; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2019 |
Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline
Topics: BRCA2 Protein; Carcinoma, Renal Cell; Chemoradiotherapy, Adjuvant; Female; Germ-Line Mutation; Humans; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Multiple Primary; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2019 |
Innovations in the treatment of melanoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cancer Vaccines; DNA, Antisense; Genetic Therapy; Humans; Immunologic Factors; Melanoma; Niacinamide; Phenylurea Compounds; Proteasome Inhibitors; Sorafenib | 2004 |
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2013 |
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.
Topics: Adolescent; Adult; Child, Preschool; Enzyme Activation; Female; Gene Rearrangement; Humans; Indoles; Male; MAP Kinase Signaling System; Melanocytes; Melanoma; Middle Aged; Molecular Targeted Therapy; Nevus, Epithelioid and Spindle Cell; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib; Young Adult | 2013 |
Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Uveal Neoplasms | 2014 |
Molecular ultrasound imaging using contrast agents targeting endoglin, vascular endothelial growth factor receptor 2 and integrin.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Contrast Media; Endoglin; Female; Integrin alphaV; Intracellular Signaling Peptides and Proteins; Melanoma; Mice; Mice, Nude; Molecular Imaging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition.
Topics: Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Collagenases; Humans; Hydrogels; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Tissue Scaffolds; Vemurafenib | 2015 |
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays | 2015 |
Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Flavonoids; Flavonols; Humans; Immunohistochemistry; Melanoma; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cadherins; Cell Line, Tumor; Cell Movement; Cells, Cultured; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Flavonoids; Flavonols; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Melanoma; Mice, Nude; Mutation; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
A case series of anal melanoma including the results of treatment with imatinib in selected patients.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Agents; Anus Neoplasms; Dacarbazine; Digestive System Surgical Procedures; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Retrospective Studies; Sorafenib; Survival Rate | 2016 |
B-Raf Inhibition in the Clinic: Present and Future.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib | 2016 |
Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin.
Topics: Cell Line, Tumor; Cell Proliferation; Genes, ras; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Receptors, Retinoic Acid; Sorafenib; Xanthones | 2016 |
Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Ceramides; Drug Synergism; Humans; Liposomes; Melanoma; Mitogen-Activated Protein Kinases; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib | 2008 |
Effectively targeting BRAF in melanoma: a formidable challenge.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides; Treatment Outcome | 2008 |
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polycythemia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Searching for the Achilles' heel of melanoma cells: new treatment modalities.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Clinical Trials as Topic; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Melanoma; Niacinamide; Organoselenium Compounds; Phenylurea Compounds; Pyridines; Pyrimethamine; Skin Neoplasms; Sorafenib; Treatment Outcome; Urea; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Male; Melanoma; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Pyridines; Skin; Skin Diseases; Skin Neoplasms; Sorafenib | 2009 |
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
Topics: Apoptosis; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glutamic Acid; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Valine | 2009 |
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyridines; Pyrimidines; Receptor, EphA2; Sorafenib; Temozolomide; Thiazoles | 2008 |
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzenesulfonates; Dacarbazine; Humans; Male; Melanoma; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Temozolomide; Treatment Outcome | 2008 |
Targeting metastatic melanoma.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents; Benzenesulfonates; Cancer Vaccines; Clinical Trials as Topic; CTLA-4 Antigen; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Skin Neoplasms; Sorafenib; Thionucleotides | 2008 |
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Quinoxalines; Skin Neoplasms; Sorafenib; Substrate Specificity; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
Topics: Abdomen, Acute; Aged; Antineoplastic Agents; Benzenesulfonates; Colectomy; Colonic Diseases; Diarrhea; Fatal Outcome; Humans; Ileostomy; Intestinal Perforation; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib; Ulcer | 2009 |
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Humans; Imatinib Mesylate; Imidazoles; Inhibitory Concentration 50; Melanoma; Mice; Microsomes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Sorafenib | 2009 |
Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Child, Preschool; Cyclophosphamide; Dacarbazine; Female; Humans; Melanoma; Melanosis; Meningeal Neoplasms; Neurocutaneous Syndromes; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide; Treatment Outcome | 2010 |
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Disease Progression; Female; Gene Silencing; Humans; Indoles; Male; Melanoma; Middle Aged; Nevus; Niacinamide; Phenols; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Sensitivity and Specificity; Skin Neoplasms; Sorafenib; Young Adult | 2009 |
The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Colony-Forming Units Assay; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique; Furans; Humans; Immunoenzyme Techniques; Immunosuppression Therapy; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrimidines; ras Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2010 |
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Topics: Animals; Benzenesulfonates; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Enzyme Activation; Humans; Immunoprecipitation; MAP Kinase Signaling System; Melanoma; Mice; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; ras Proteins; Sorafenib; Transfection | 2009 |
Optimal de novo design of MRM experiments for rapid assay development in targeted proteomics.
Topics: Algorithms; Animals; Artificial Intelligence; Benzenesulfonates; Cell Line, Tumor; Chromatography, High Pressure Liquid; Female; Humans; Linear Models; Markov Chains; Mass Spectrometry; Melanoma; Mice; Niacinamide; Peptide Fragments; Phenylurea Compounds; Proteome; Proteomics; Pyridines; Reproducibility of Results; Sorafenib | 2010 |
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Skin Neoplasms; Sorafenib | 2010 |
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Benzenesulfonates; Cell Line, Tumor; Endoplasmic Reticulum; Farnesyltranstransferase; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factor CHOP | 2011 |
Oncogenic RAF: a brief history of time.
Topics: Benzenesulfonates; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides; Time Factors; Vemurafenib | 2010 |
Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Drug Administration Routes; Follow-Up Studies; Humans; Leg; Male; Melanoma; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib | 2010 |
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; Clinical Trials, Phase II as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger.
Topics: Amino Acid Substitution; Animals; Benzenesulfonates; Cation Transport Proteins; Cell Movement; Cell Size; Extracellular Signal-Regulated MAP Kinases; HEK293 Cells; HeLa Cells; Humans; Hydrogen-Ion Concentration; Indoles; Melanoma; Mutation, Missense; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Isoforms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins B-raf; Pyridines; Rabbits; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfonamides | 2011 |
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Hep G2 Cells; Humans; Liver Neoplasms; Melanoma; Mice; Mice, SCID; Niacinamide; Oncolytic Virotherapy; Phenylurea Compounds; Pyridines; Sorafenib; Vaccinia virus; Xenograft Model Antitumor Assays | 2011 |
Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.
Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Chemokine CXCL5; Dichlororibofuranosylbenzimidazole; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Genes, Reporter; Half-Life; Humans; Immunotherapy, Active; Interleukin-8; Leupeptins; MAP Kinase Kinase Kinases; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyridines; Receptors, Interleukin-8B; RNA Stability; RNA, Messenger; RNA, Small Interfering; Sorafenib; Transfection; Tristetraprolin; Tumor Cells, Cultured; Vaccination | 2011 |
[News on melanoma from the 2010 Dermatology Days in Paris].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Dermatology; Evidence-Based Medicine; Humans; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Skin Neoplasms; Sorafenib; Temozolomide; Treatment Outcome | 2011 |
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Genes, Dominant; Humans; Indoles; Melanocytes; Melanoma; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Fibroblast Growth Factor; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2011 |
Setting up a kinase discovery and development project.
Topics: Adenosine Triphosphate; Animals; Crystallography, X-Ray; Drug Discovery; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Enzyme Activation; Enzyme Assays; Humans; Indoles; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Solubility; Sorafenib; Structure-Activity Relationship; Sulfonamides | 2012 |
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glutamic Acid; Indoles; Melanoma; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Gene Expression; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Melanoma; Mice; Mice, Nude; Mitochondria; Necrosis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Transport; Proto-Oncogene Proteins c-mdm2; Pyridines; RNA Interference; Sorafenib; Spiro Compounds; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Design, synthesis, and antiproliferative activity of 3,4-diarylpyrazole-1-carboxamide derivatives against melanoma cell line.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyridines; Sorafenib; Structure-Activity Relationship | 2011 |
Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways.
Topics: Anthracenes; Benzenesulfonates; Cell Death; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; Melanoma; Morpholines; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib | 2011 |
Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Butadienes; Cell Survival; Dacarbazine; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fatal Outcome; Female; Genes, ras; Humans; Melanoma; Molecular Targeted Therapy; Mutation; Niacinamide; Nitriles; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Phosphorylation; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Signal Transduction; Sorafenib; Treatment Outcome | 2011 |
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.
Topics: Antineoplastic Agents; Benzophenones; Boronic Acids; Bortezomib; Cell Proliferation; Conjunctival Neoplasms; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazines; Ribonucleases; Sorafenib; Tumor Cells, Cultured | 2013 |
Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Diclofenac; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Phospholipases A2, Cytosolic; Signal Transduction; Skin Neoplasms; Small Molecule Libraries; Sorafenib | 2012 |
B-RAF is a therapeutic target in melanoma.
Topics: Benzenesulfonates; Cell Line, Tumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2004 |
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Topics: Animals; Apoptosis; Benzenesulfonates; Cell Growth Processes; Cell Line, Tumor; Humans; MAP Kinase Signaling System; Melanoma; Mice; Mutation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA, Small Interfering; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Benzenesulfonates; Caspases; Cell Line, Tumor; Cell Nucleus; Cytochromes c; Humans; Intracellular Signaling Peptides and Proteins; Melanoma; Mitochondria; Mitochondrial Proteins; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Sorafenib | 2006 |
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Collagen; Drug Combinations; Endothelial Cells; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Humans; Kidney Neoplasms; Laminin; Melanoma; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteoglycans; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib | 2006 |
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.
Topics: Androstadienes; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Humans; MAP Kinase Signaling System; Melanoma; Neoplasm Invasiveness; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib; Wortmannin | 2007 |
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Topics: Benzenesulfonates; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA Interference; RNA, Small Interfering; Sorafenib; Transfection; Up-Regulation | 2007 |
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Movement; Cell Proliferation; Disease Models, Animal; Endothelial Cells; Eye Neoplasms; Humans; In Vitro Techniques; Lenalidomide; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Thalidomide; Xenograft Model Antitumor Assays | 2007 |
GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines.
Topics: Apoptosis; Benzenesulfonates; Cell Adhesion; Cell Death; Cell Line, Tumor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Melanoma; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
Topics: Androstadienes; Apoptosis; Benzenesulfonates; Butadienes; Cell Line, Tumor; Cell Proliferation; Chromones; Down-Regulation; Flavonoids; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mitogen-Activated Protein Kinase Kinases; Morpholines; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sirolimus; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Wortmannin | 2008 |
Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Lower Extremity; Lymphatic Metastasis; Lymphedema; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |